A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas

TY - JOUR

T1 - A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas

AU - 2022 NTAP Cutaneous Neurofibroma Symposium Participants

AU - Blakeley, Jaishri O.

AU - Le, Lu Q.

AU - Lee, Sang Y.

AU - Ly, Ina

AU - Rhodes, Steven D.

AU - Romo, Carlos G.

AU - Sarin, Kavita Y.

AU - Staedtke, Verena

AU - Steensma, Matthew R.

AU - Wolkenstein, Pierre

AU - Largaespada, David

AU - Serra, Eduard

AU - Haniffa, Muzlifah

AU - Bakker, Annette

AU - McCormick, Frank

AU - Cagan, Ross L.

AU - Ju, William

AU - Stemmer-Rachamimov, Anat

AU - Grimes, Kevin

AU - Topilko, Piotr

AU - Kornacki, Deanna

AU - Kelly, Kristen M.

AU - Gottesman, Sally

AU - York, Zachary

AU - Epps, Roselyn

N1 - Funding Information: The authors thank the 2022 NTAP Cutaneous Neurofibroma Symposium participants: Team 1 (cNF Pathology and Biology) members: David Largaespada (University of Minnesota), Eduard Serra (The Institute for Health Science Research Germans Trias i Pujol (IGTP)), and Muzlifah Haniffa (Newcastle University / Wellcome Sanger Institute); Team 2 (Therapeutic Targets for cNF Treatment) members: Annette Bakker (Children's Tumor Foundation), Frank McCormick (UCSF Helen Diller Family Comprehensive Cancer Center), Ross L. Cagan (University of Glasgow), and William Ju (Advancing Innovation in Dermatology, Inc.); Team 3 (Preclinical Testing and Assays) members: Anat Stemmer-Rachamimov (Massachusetts General Hospital), Kevin Grimes (Stanford University School of Medicine), and Piotr Topilko (Institut National de la Sante Et de la Recherche Medicale (INSERM)); and Team 4 (Human Clinical Trials: Therapeutic Strategy and Development) members: Deanna Kornacki (Incyte Corporation), Kristen M. Kelly (University of California, Irvine), Sally Gottesman (NTAP Founder and Encounter), Zachary York (Founder and Creative Director), and Roselyn Epps (US Food and Drug Administration). The authors also thank Tim Phelps for illustration assistance. This publication was supported by funding from the Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the Johns Hopkins University School of Medicine. This publication was supported by funding from the Neurofibromatosis Therapeutic Acceleration Program (NTAP) at the Johns Hopkins University School of Medicine. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of The Johns Hopkins University School of Medicine. Conceptualization: JOB; Writing - Original Draft Preparation: JOB, CGR; Writing - Review and Editing: JOB, LQL, SYL, IL, SDR, CGR, KYS, VS, MRS, PW, Its contents are solely the responsibility of the authors and do not necessarily represent the official views of The Johns Hopkins University School of Medicine. Funding Information: IL, JOB, SL, CR, VS, SR, KS, MS have received support via Neurofibromatosis Therapeutic Acceleration Progam (NTAP) at Johns Hopkins University. IL, JOB, MS, SR receive research support from the Department of Defense. IL and JB are a consultants for SpringWorks Therapeutics. KYS is on scientific advisory for NFlection Therapeutics. PW is an expert for AstraZeneca, Springworks, and Alexion. The remaining authors state no conflict of interest.

PY - 2023/8

Y1 - 2023/8

UR - http://www.scopus.com/inward/record.url?scp=85162899121&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2022.11.027

DO - 10.1016/j.jid.2022.11.027

M3 - Comment/debate

C2 - 37354152

AN - SCOPUS:85162899121

SN - 0022-202X

VL - 143

SP - 1351

EP - 1357

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

IS - 8

ER -